Levalbuterol versus albuterol

Current Allergy and Asthma Reports

Volumn 9, Issue 5, 2009, Pages 401-409

  Ameredes, Bill T ^b   Calhoun, William J ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CYCLIC AMP; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 11; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LEVALBUTEROL; PLACEBO; PROPRANOLOL; SALBUTAMOL; STEROID;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CALCIUM CELL LEVEL; CLINICAL TRIAL; COST CONTROL; CYTOKINE RELEASE; DISEASE EXACERBATION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HISTAMINE RELEASE; HUMAN; IMMUNOMODULATION; INFLAMMATION; METERED DOSE INHALER; NONHUMAN; RACEMIC MIXTURE; REVIEW; SMOOTH MUSCLE CONTRACTILITY; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANIMALS; ASTHMA; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 68949100527     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-009-0058-6     Document Type: Review

References (80)

1. Busse W, Banks-Schlegel S, Noel P, et al.: Future research directions in asthma: An NHLBI Working Group report. Am J Respir Crit Care Med 2004, 170:683-690.
2. Fuhlbrigge AL, Adams RJ, Guilbert TW, et al.: The burden of asthma in the United States: Level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med 2002, 166:1044-1049.
3. Gilberg K, Laouri M, Wade S, Isonaka S: Analysis of medication use patterns: Apparent overuse of antibiotics and underuse of prescription drugs for asthma, depression, and CHF. J Manag Care Pharm 2003, 9:232-237.
4. Reed S, Diggle S, Cushley MJ, et al.: Assessment and management of asthma in an accident and emergency department. Thorax 1985, 40:897-902.
5. Penn RB, Frielle T, McCullough JR, et al.: Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors. Clin Rev Allergy Immunol 1996, 14:37-45.
6. Cockcroft DW, McParland CP, Britto SA, et al.: Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993, 342:833-837.
7. Spitzer WO, Suissa S, Ernst P, et al.: The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992, 326:501-506.
8. Abramson MJ, Bailey MJ, Couper FJ, et al.: Are asthma medications and management related to deaths from asthma? Am J Respir Crit Care Med 2001, 163:12-18.
9. Nowak RM, Emerman CL, Schaefer K, et al.: Levalbuterol compared with racemic albuterol in the treatment of acute asthma: Results of a pilot study. Am J Emerg Med 2004, 22:29-36.
10. Boulton DW, Fawcett JP: Enantioselective disposition of salbutamol in man following oral and intravenous administration. Br J Clin Pharmacol 1996, 41:35-40.
11. Boulton DW, Fawcett JP: The pharmaWokinetics of levosalbutamol: what are the clinical implications? Clin Pharmacokinet 2001, 40:23-40.
12. Morgan DJ, Paull JD, Richmond BH, et al.: Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol 1986, 22:587-593.
13. Gumbhir-Shah K, Kellerman DJ, DeGraw S, et al.: Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. J Clin Pharmacol 1998, 38:1096-1106.
14. Naidu Sjosward K, Josefsson M, Ahlner J, et al.: Metabolism of salbutamol differs between asthmatic patients and healthy volunteers. Pharmacol Toxicol 2003, 92:27-32.
15. Eaton EA, Walle UK, Wilson HM, et al.: Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin Pharmacol 1996, 41:201-206.
16. Lipworth BJ, Clark DJ, Koch P, Arbeeny C: Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax 1997, 52:849-852.
17. Gumbhir-Shah K, Kellerman DJ, DeGraw S, et al.: Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. Pulm Pharmacol Ther 1999, 12:353-362.
18. Dhand R, Goode M, Reid R, et al.: Preferential pulmonary retention of (S)-albuterol after inhalation of racemic al buterol. Am J Respir Crit Care Med 1999, 160:1136-1141.
19. Hartley D, Middlemiss D: Absolute configuration of the optical isomers of salbutamol. J Med Chem 1971, 14:995-996.
20. Page CP, Morley J: Contrasting properties of albuterol stereoisomers. J Allergy Clin Immunol 1999, 104:S31-S41.
21. CullumAVA, Farmer JB, Jack D, Levy GP: Salbutamol: a new, selective betaadrenoceptive receptor stimulant. Br J Pharmacol 1969, 35:141-151.
22. Yamaguchi H, McCullough JR: S-albuterol exacerbates calcium responses to carbachol in airway smooth muscle cells. Clin Rev Allergy Immunol 1996, 14:47-55.
23. Zhang XY, Zhu FX, Olszewski MA, Robinson NE: Effects of enantiomers of beta 2-agonists on ACh release and smooth muscle contraction in the trachea. Am J Physiol 1998, 274:L32-L38.
24. Johansson F, Rydberg I, Aberg G, Andersson RG: Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol 1996, 14:57-64.
25. Delmotte P, Sanderson MJ: Effects of albuterol isomers on the contraction and Ca2+ signaling of small airways in mouse lung slices. Am J Respir Cell Mol Biol 2008, 38:524-531.
26. Mitra S, Ugur M, Ugur O, et al.: (S)-Albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol 1998, 53:347-354.
27. Mazzoni L, Naef R, Chapman ID, Morley J: Hyperresponsiveness of the airways following exposure of guinea-pigs to racemic mixtures and distomers of beta 2-selective sympathomimetics. Pulm Pharmacol 1994, 7:367-376.
28. Keir S, Page C, Spina D: Bronchial hyperresponsiveness induced by chronic treatment with albuterol: Role of sensory nerves. J Allergy Clin Immunol 2002, 110:388-394.
29. Vargaftig BB: Modifications of experimental bronchopulmonary hyperresponsiveness. Am J Respir Crit Care Med 1997, 156:S97-S102.
30. Henderson WR Jr, Banerjee ER, Chi EY: Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. J Allergy Clin Immunol 2005, 116:332-340.
31. Agrawal DK, Ariyarathna K, Kelbe PW: (S)-Albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol 2004, 113:503-510.
32. Templeton AG, Chapman ID, Chilvers ER, et al.: Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther 1998, 11:1-6.
33. Lazaar AL, Amrani Y, Hsu J, et al.: CD40-mediated signal transduction in human airway smooth muscle. J Immunol 1998, 161:3120-3127.
34. Farmer P, Pugin J: Beta-adrenergic agonists exert their "anti-inflammatory" effects in monocytic cells through the IkappaB/NF-kappaB pathway. Am J Physiol Lung Cell Mol Physiol 2000, 279:L675-L682.
35. Roth M, Johnson PR, Rudiger JJ, et al.: Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002, 360:1293-1299.
36. Barnes PJ: Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002, 19:182-191.
37. Currie GP, Stenback S, Lipworth BJ: Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. Br J Clin Pharmacol 2003, 56:11-17.
38. Cho SH, Hartleroad JY, Oh CK: (S)-albuterol increases the production of histamine and IL-4 in mast cells. Int Arch Allergy Immunol 2001, 124:478-484.
39. Leff AR, Herrnreiter A, Naclerio RM, et al.: Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils. Pulm Pharmacol Ther 1997, 10:97-104.
40. Volcheck GW, Kelkar P, Bartemes KR, et al.: Effects of (R)- and (S)-isomers of beta-adrenergic agonists on eosinophil response to interleukin-5. Clin Exp Allergy 2005, 35:1341-1346.
41. Baramki D, Koester J, Anderson AJ, Borish L: Modulation of T-cell function by (R)- and (S)-isomers of albuterol: Antiinflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol 2002, 109:449-454.
42. Milligan G, Bond RA: Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 1997, 18:468-474.
43. Chidiac P, Hebert TE, Valiquette M, et al.: Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol 1994, 45:490-499.
44. Elias JA, Wu Y, Zheng T, Panettieri R: Cytokine- and virus-stimulated airway smooth muscle cells produce IL-11 and other IL-6-type cytokines. Am J Physiol 1997, 273:L648-L655.
45. Saunders MA, Mitchell JA, Seldon PM, et al.: Release of granulocyte-macrophage colony stimulating factor by human cultured airway smooth muscle cells: Suppression by dexamethasone. Br J Pharmacol 1997, 120:545-546.
46. Panettieri RA JrI Airway smooth muscle: immunomodulatory cells that modulate airway remodeling? Respir Physiol Neurobiol 2003, 137:277-293.
47. Endo T, Uchida Y, Nomura A, et al.: Activated eosinophils stimulate endothelin-1 release from airway epithelial cells by direct adherence via adhesion molecules. Pulm Pharmacol Ther 1997, 10:81-87.
48. Hallsworth MP, Soh CP, Twort CH, et al.: Cultured human airway smooth muscle cells stimulated by interleukin-1beta enhance eosinophil survival. Am J Respir Cell Mol Biol 1998, 19:910-919.
49. Ameredes BT, Calhoun WJ: Modulation of GM-CSF release by enantiomers of beta agonists in human airway smooth muscle. J Allergy Clin Immunol 2005, 116:65-72.
50. Hallsworth MP, Twort CH, Lee TH, Hirst SJ: Beta(2)-adrenoceptor agonists inhibit release of eosinophil-activating cytokines from human airway smooth muscle cells. Br J Pharmacol 2001, 132:729-741.
51. Tomlinson PR, Wilson JW, Stewart AG: Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: relationship to elevated cAMP levels. Biochem Pharmacol 1995, 49:1809-1819.
52. Ibe BO, Abdallah MF, Raj JU: Mechanisms by which S-albuterol induces human bronchial smooth muscle cell proliferation. Int Arch Allergy Immunol 2008, 146:321-333.
53. Ferrada MA, Gordon EL, Jen KY, et al.: (R)-albuterol decreases immune responses: Role of activated T cells. Respir Res 2008, 9:3.
54. Auais A, Wedde-Beer K, Piedimonte G: Anti-inflammatory effect of albuterol enantiomers during respiratory syncytial virus infection in rats. Pediatr Pulmonol 2005, 40:228-234.
55. Perrin-Fayolle M, Blum PS, Morley J, et al.: Differential responses of asthmatic airways to enantiomers of albuterol. Implications for clinical treatment of asthma. Clin Rev Allergy Immunol 1996, 14:139-147.
56. Cockcroft DW, Swystun VA: Effect of single doses of Ssalbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax 1997, 52:845-848.
57. Cockcroft DW, Davis BE, Swystun VA, Marciniuk DD: Tolerance to the bronchoprotective effect of beta2-agonists: Comparison of the enantiomers of salbutamol with racemic salbutamol and placebo. J Allergy Clin Immunol 1999, 103:1049-1053.
58. Ramsay CM, Cowan J, Flannery E, et al.: Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma. Eur J Clin Pharmacol 1999, 55:353-359.
59. Sjosward KN, Hmani M, Davidsson A, et al.: Single-isomer R-salbutamol is not superior to racemate regarding protection for bronchial hyperresponsiveness. Respir Med 2004, 98:990-999.
60. Jacobson GA, Chong FV, Wood-Baker R: (R,S)-salbutamol plasma concentrations in severe asthma. J Clin Pharm Ther 2003, 28:235-238.
61. Nelson HS, Bensch G, Pleskow WW, et al.: Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998, 102:943-952.
62. Ahrens R, Weinberger M: LevalbAterol and racemic albuterol: are there therapeutic differences? J Allergy Clin Immunol 2001, 108:681-684.
63. Pleskow WW, Nelson HS, Schaefer K, et al.: Pairwise comparison of levalbuterol versus racemic albuterol in the treatment of moderate-to-severe asthma. Allergy Asthma Proc 2004, 25:429-436.
64. Lotvall J, Palmqvist M, Arvidsson P, et al.: The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001, 108:726-731.
65. Gawchik SM, Saccar CL, Noonan M, et al.: The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999, 103:615-621.
66. Milgrom H, Skoner DP, Bensch G, et al.: Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001, 108:938-945.
67. Carl JC, Myers TR, Kirchner HL, Kercsmar CM: Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003, 143:731-736.
68. Nowak R, Emerman C, Hanrahan JP, et al.: A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med 2006, 24:259-267.
69. Hardasmalani MD, DeBari V, Bithoney WG, Gold N: Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care 2005, 21:415-419.
70. Ralston ME, Euwema MS, Knecht KR, et al.: Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: A randomized controlled trial. J Emerg Med 2005, 29:29-35.
71. Qureshi F, Zaritsky A, Welch C, et al.: Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005, 46:29-36.
72. Quinn C: The cost effectiveness of levalbuterol versus racemic albuterol. Am J Manag Care 2004, 10:S153-S157.
73. Pesola GR, Coelho Da'Costa V: Albuterol or levalbuterol for the treatment of asthma. Internet J Asthma Allergy Immunol 2004, 3. Available at http://www.ispub.com.
74. Pikarsky RS, Acevedo RA: Clinical and economic impact resulting from a hospitalwide conversion from racemic albuterol to levalbuterol. Chest 2002, 122:146S.
75. Pikarsky RS, Acevedo RA, Roman C, Farrell T: Comparison of rates of breakthrough treatments during a conversion from racemic albuterol to levalbuterol. Chest 2002, 122:125S.
76. Donohue JF, Hanania NA, Ciubotaru RL, et al.: Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: A 2-week, multicenter, randomized, open-label study. Clin Ther 2008, 30:989-1002.
77. Berger WE, Ames DE, Harrison D: A patient satisfaction survey comparing levalbuterol with racemic albuterol in children. Allergy Asthma Proc 2004, 25:437-444.
78. Masoli M, Fabian D, Holt S, Beasley R: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004, 59:469-478.
79. Skrepnek GH, Skrepnek SV: Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma. Am J Manag Care 2004, 10:S129-S138.
80. Cripps A, Riebe M, Schulze M, Woodhouse R: Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000, 94(Suppl B):S3-S9.